Sökning: (L773:2055 6837 OR L773:2055 6845) > (2018) > Antithrombotic ther...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05359naa a2200505 4500 | |
001 | oai:DiVA.org:uu-351634 | |
003 | SwePub | |
008 | 180607s2018 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3516342 URI |
024 | 7 | a https://doi.org/10.1093/ehjcvp/pvy0022 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Goto, Shinyau Tokai Univ, Sch Med, Dept Med Cardiol, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan.4 aut |
245 | 1 0 | a Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation :b insights from ARISTOTLE |
264 | c 2018-01-29 | |
264 | 1 | b Oxford University Press (OUP),c 2018 |
338 | a print2 rdacarrier | |
520 | a Aims We investigated baseline characteristics, antithrombotic use, and clinical outcomes of patients with atrial fibrillation (AF) and a thrombo-embolic event in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) study to better inform the care of these high-risk patients. Method and results Thrombo-embolic events were defined as stroke (ischaemic or unknown cause) or systemic embolism (SE). Clinical outcomes were estimated using the Kaplan-Meier method. All-cause mortality and International Society on Thrombosis and Haemostasis (ISTH) major bleeding after events were analysed using a Cox proportional hazards model with time-dependent covariates. Of 18 201 patients in ARISTOTLE, 365 experienced a thrombo-embolic event [337 strokes (ischaemic or unknown cause), 28 SE]; 46 (12.6%) of which were fatal. In the 30 days before and after a thrombo-embolic event, 11% and 37% of patients, respectively, were not taking an oral anticoagulant. During follow-up (median 1.8 years), 22 patients (7.1%/year) had a recurrent stroke, 97 (30.1%/year) died, and 10 (6.7%/year) had major bleeding. Compared with patients without a thrombo-embolic event, the short-and long-term adjusted hazards of death in patients with a thrombo-embolic event were high [<= 30 days: hazard ratio (HR) 54.3%, 95% confidence interval (95% CI) 41.4-71.3; >30 days: HR 3.5, 95% CI 2.5-4.8; both P<0.001]. The adjusted hazards of major bleeding were also high short-term (HR 10.37, 95% CI 3.87-27.78; P<0.001) but not long-term (HR 1.7, 95% CI: 0.77-3.88; P=0.18). Conclusions Thrombo-embolic events were rare but associated with high short-and long-term morbidity and mortality. Substantial numbers of patients are not receiving oral anticoagulattherapy before and, despite this risk, after a first thrombo-embolic event. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng |
653 | a Antithrombotic therapy | |
653 | a Thrombo-embolic events | |
653 | a Atrial fibrillation | |
700 | 1 | a Merrill, Peteru Duke Hlth, Duke Clin Res Inst, Dept Stat, 2400 Pratt St, Durham, NC 27705 USA.4 aut |
700 | 1 | a Wallentin, Lars,d 1943-u Uppsala universitet,Kardiologi,Uppsala kliniska forskningscentrum (UCR)4 aut0 (Swepub:uu)larswall |
700 | 1 | a Wojdyla, Daniel M.u Duke Hlth, Duke Clin Res Inst, Dept Stat, 2400 Pratt St, Durham, NC 27705 USA.4 aut |
700 | 1 | a Hanna, Michaelu Bristol Myers Squibb, 3551 Lawrenceville Princeton, Lawrence Township, NJ 08648 USA.4 aut |
700 | 1 | a Avezum, Alvarou Dante Pazzanese, Inst Cardiol, Res Div, Ave Dante Pazzanese 500, BR-04012909 Sao Paulo, SP, Brazil.4 aut |
700 | 1 | a Easton, J. Donaldu Univ Calif San Francisco, Dept Neurol, Box 0663,675 Nelson Rising Lane,412, San Francisco, CA 94158 USA.4 aut |
700 | 1 | a Harjola, Veli-Pekkau Univ Helsinki, Cent Hosp, Dept Med, Div Emergency Care, POB 340, Helsinki 00029, Hus, Finland.4 aut |
700 | 1 | a Huber, Kurtu Med Univ Vienna, Wilhelminenspital, Dept Cardiol, Spitalgasse 23, A-1090 Vienna, Austria.4 aut |
700 | 1 | a Lewis, Basil S.u Technion, Ruth & Bruce Rappaport Sch Med, Lady Davis Carmel Med Ctr, Dept Cardiol, Mikhal St 7, IL-3436212 Haifa, Israel.4 aut |
700 | 1 | a Parkhomenko, Alexanderu Inst Cardiol, Dept Cardiol, Narodnoho Opolchennya St 5, UA-02000 Kiev, Ukraine.4 aut |
700 | 1 | a Zhu, Junu Fuwai Hosp, Beijing, Peoples R China.4 aut |
700 | 1 | a Granger, Christopher B.u Duke Hlth, Duke Clin Res Inst, Dept Med, Div Cardiol, 2400 Pratt St, Durham, NC 27705 USA.4 aut |
700 | 1 | a Lopes, Renato D.u Duke Hlth, Duke Clin Res Inst, 2400 Pratt St, Durham, NC 27705 USA.4 aut |
700 | 1 | a Alexander, John H.u Duke Hlth, Duke Clin Res Inst, Dept Med, Div Cardiol, 2400 Pratt St, Durham, NC 27705 USA.4 aut |
710 | 2 | a Tokai Univ, Sch Med, Dept Med Cardiol, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan.b Duke Hlth, Duke Clin Res Inst, Dept Stat, 2400 Pratt St, Durham, NC 27705 USA.4 org |
773 | 0 | t European Heart Journal - Cardiovascular Pharmacotherapyd : Oxford University Press (OUP)g 4:2, s. 75-81q 4:2<75-81x 2055-6837x 2055-6845 |
856 | 4 | u https://academic.oup.com/ehjcvp/article-pdf/4/2/75/24260579/pvy002.pdf |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-351634 |
856 | 4 8 | u https://doi.org/10.1093/ehjcvp/pvy002 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.